Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 79

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 79
---
 ongoing government shutdown, the SEC will
not review any registration statement or declare any registration statement effective. Our registration statement has automatically become
effective on October 29, 2025 in accordance with Section 8(a) of the Securities Act. While we believe we have satisfactorily addressed
all SEC comments on the registration statement that we received before the shutdown, we could receive comments from the SEC after completion
of this offering, and those comments could obligate us to modify, reformulate, add to or exclude certain information presented in this
prospectus. Any such modification, reformulation, addition or exclusion could be significant. Whether or not we receive comments from
the SEC, neither the SEC nor any state securities commission has approved or disapproved of these securities or determined whether this
prospectus is truthful or complete.

NewGenIvf operates in a highly regulated industry and must comply with a significant number of complex and evolving requirements. Any lack of requisite approvals, licenses, or permits applicable to NewGenIvf’s business may have a material and adverse impact on NewGenIvf’s business, financial condition, and results of operations.

The operations of NewGenIvf
are subject to various laws, rules and regulations at the national, regional and local levels in Thailand, Cambodia, Kyrgyzstan, Hong
Kong, United Arab Emirates, United States of America and other applicable jurisdictions. Such laws and regulations mainly relate to (i) the
licensing of local and foreign medical professionals, nursing professionals, medical technology professionals, pharmaceutical professions
and other applicable licensing; (ii) the licensing, registration, and accreditation of medical facilities, laboratories, including
but not limited to the licensing, registration, and accreditation of persons performing related activities; (iii) the privacy and
security of confidential patient medical records; (iv) the corporate practice of medicine; (v) healthcare fraud and abuse laws;
(vi) the donation and transplantation of human cells, tissues and organs; (vii) potential prohibition on surrogacy or providing
intermediary assistance in surrogacy; and (viii) licensing and approval of the accommodation provided as parts of the services.

<div align='center'>44</div>

NewGenIvf has attempted to
structure its operations to comply with laws, regulations and other requirements applicable to it directly and to its clients and vendors,
but there can be no assurance that its operations will not be challenged or impacted by regulatory authorities or enforcement initiatives,
or that the relevant authorities in each jurisdiction